0
0
Recent research published in Alzheimer’s & Dementia reveals a critical new mechanism behind the early stages of Alzheimer’s disease (AD), implicating a synergistic interaction between amyloid-beta (Aβ) peptides and fibrinogen, a major blood protein. The findings, led by Erin Norris and her team in the laboratory of Sidney Strickland at Rockefeller University, suggest that when Aβ and fibrinogen bind together, they form abnormal clots that are resistant to degradation and trigger early disease pathology—even at low concentrations.
The study builds on decades of research into the abnormal plaques and tangles characteristic of the Alzheimer’s brain, but shifts focus toward the role of the brain’s vascular system. While Aβ and fibrinogen each require high levels to cause significant damage on their own, the combination of these proteins at low concentrations proved highly toxic to synapses and led to hallmark features of Alzheimer’s, including neuroinflammation, synapse loss, and disruption of the blood-brain barrier.
Using both brain slices and live mice, the researchers demonstrated that the Aβ/fibrinogen complex is responsible for inducing blood-brain barrier leakage—an event not seen with either protein alone. This disruption allows blood proteins to infiltrate the brain, compounding neuronal damage. The team confirmed the complex’s role by using antibodies to block Aβ-fibrinogen binding, which reduced harmful effects.
Notably, mice exposed to the Aβ/fibrinogen complex showed elevated levels of phospho-tau181, a biomarker for early Alzheimer’s in humans. This suggests that the complex may drive disease processes long before cognitive symptoms appear, opening new possibilities for early intervention and prevention.
“It’s not a simple disease,” says Elisa Nicoloso Simões-Pires, a research associate on the team. “A lot of other factors can induce neurotoxicity, and we certainly do not propose that inhibiting this complex formation would cure AD. But perhaps targeting this complex would alleviate some of the pathologies and be even more effective in combination with other therapies.”
The study highlights the Aβ/fibrinogen complex as a promising new drug target and reinforces the importance of vascular health in Alzheimer’s disease.
Disclaimer:
This news article is based on recent scientific research and is intended for informational purposes only. The findings are preliminary and may require further validation in clinical settings. This article does not constitute medical advice, and readers should consult healthcare professionals for diagnosis and treatment options related to Alzheimer’s disease.
